The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis

摘要: The febrile neutropenia (FN) rates reported with the docetaxel 75 mg/m(2) plus cyclophosphamide 600 (TC) regimen given every 3 weeks vary from 4 to 69 % in early-stage breast cancer (ESBC) patients. This creates uncertainty as whether patients receiving TC should also receive granulocyte colony-stimulating factor primary prophylaxis (G-CSFpp), which is recommended when chemotherapy regimens have ≥20 FN rate. We conducted a meta-analysis of published studies determine rate regimen, its dependence on patients' age, and efficacy G-CSFpp reducing it ESBC systematically searched literature via PUBMED using following terms: 'docetaxel', 'cyclophosphamide', 'febrile neutropenia', 'breast cancer'. Inclusion criteria were full text peer-reviewed clinical English reporting relationship G-CSFpp. Comprehensive software was used for all statistical analyses. Eight (N = 1542 patients) included our meta-analysis. pooled mean 23.2 (95 confidence interval (CI) 6.9-55.2 %; Q 218.17, I (2) 97.7). risk <65 years old lower by 67.7 compared that ≥65 (pooled odds ratio (OR) 0.323; 95 CI 0.127-0.820; P 0.017). reduced 92.3 OR 0.077; 0.013-0.460; 0.005). Our demonstrated associated risk, significantly higher improved be considered especially those old.